PSTV Stock Risk & Deep Value Analysis
Plus Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on PSTV
We analyzed Plus Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PSTV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
PSTV Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Plus Therapeutics Inc (PSTV)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$86.42M
PSTV Deep Value Analysis
Compare PSTV to Similar Stocks
See how Plus Therapeutics Inc stacks up against related companies in our head-to-head analysis.
PSTV Red Flags & Warning Signs
- âš
Negative or inconclusive clinical trial results for RNL
- âš
Significant adverse events reported in ongoing trials
- âš
Further substantial share dilution without corresponding clinical progress
- âš
Regulatory delays for trial progression or approvals
Unlock PSTV Red Flags & Risk Warnings
Create a free account to see the full analysis
PSTV Financial Health Metrics
Market Cap
$86.42M
PSTV Competitive Moat Analysis
Sign in to unlockMoat Rating
None
Moat Trend
Stable
Moat Sources
1 Identified
The potential for a durable moat is entirely contingent on successful clinical trials, regulatory approval, and subsequent market adoption. Until then, the intellectual property provides a theoretical moat, but one that is highly susceptible to clinical failure or competitive advancements.
PSTV Competitive Moat Analysis
Sign up to see competitive advantages
PSTV Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Interim data update from ReSPECT-GBM Phase 2/ReSPECT-LM clinical trials (Estimated Q2 2026)
- •Potential new equity offering to extend cash runway (Likely Q1/Q2 2026)
Medium-Term (6-18 months)
- •Top-line data from ReSPECT-GBM Phase 2 clinical trial (Estimated late 2026/early 2027)
- •Expansion of RNL into additional oncology indications or trial sites
Long-Term (18+ months)
- •Successful Phase 3 trial initiation and eventual regulatory filing (BLA)
- •Strategic partnership or licensing agreement for RNL commercialization
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
PSTV Bull Case: What Could Go Right
- ✓
Positive clinical trial data readouts for RNL (efficacy and safety)
- ✓
Announcements of new strategic partnerships or non-dilutive funding
- ✓
Evidence of improving cash runway and reduced reliance on dilutive offerings
- ✓
Negative clinical data or significant trial delays/adverse events
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
